FOXO4-DRI is a synthetic D-retro-inverso peptide supplied as a lyophilised research material. It is studied in laboratory models of cellular senescence and the FOXO4–p53 protein interaction.
This material is not supplied as a medicine, treatment, supplement or consumer product. It is not for human or veterinary use, consumption or administration, and is not intended to diagnose, treat, cure or prevent any disease.
Compound overview
Research context
DRI means D-retro-inverso: the reference construct uses a reversed sequence of D-amino-acid residues, with a cell-penetrating segment. Lowercase letters in the sequence above indicate D-residues; glycine is achiral. This synthetic peptide is distinct from the full-length FOXO4 protein.
Structural research identifies the p53 transactivation region as a binding site for FOXO4-DRI. Published work includes biochemical assays, cell cultures and animal models. These findings do not establish human safety, clinical effectiveness or an anti-ageing benefit. See the Research tab for linked papers and their experimental limitations.
The sequence and mass describe a published reference construct, not a certificate for the supplied batch. Counterions, water content and other formulation differences can affect analytical measurements. Verify the material against the applicable batch documentation.
Batch documentation
Independent analytical documentation is published where available for specific batches and variations. A result indicator appears only when a published record is available. Match the compound, vial size and batch identifier to the corresponding report before relying on any result.
Supply and laboratory handling
- Supplied as a 10mg vial of lyophilised research material.
- Keep the vial sealed and protected from moisture, heat and direct light.
- Use suitable laboratory controls and independently verify identity and concentration for the intended experimental model.
- Follow batch-specific storage and handling instructions where supplied.
Frequently asked questions
What is FOXO4-DRI?
A synthetic peptide used to investigate cellular senescence and FOXO4–p53 interactions in experimental systems. The scientific name uses the letter O in FOXO4.
What does DRI mean?
D-retro-inverso describes the reversed, D-amino-acid design of the published reference peptide. It is not the natural FOXO4 protein.
Do published findings establish benefits in people?
No. The selected literature concerns preclinical and mechanistic experiments, not evidence of a safe or effective human treatment.
Which vial size is available?
The current product variation is 10mg. Availability is shown above and can change.
Are laboratory results available?
A shield appears beside a variation only when a published result is available. Check the COA tab for matching records; no indicator means no product-specific result is currently displayed.
How should the material be stored?
See the Storage Guidelines tab and follow any batch-specific instructions. No human dosing, administration or injection guidance is provided.
Information reviewed 27 September 2026. References: Baar et al., 2017 (reference construct) and Bourgeois et al., 2025 (structural research).
